To analyze the impact of highly active antiretroviral therapy (HAART) on the characteristics and outcome of sarcoidosis in patients infected with human immunodeficiency virus (HIV), we identified HIV-infected patients in whom sarcoidosis was diagnosed between 1996 and 2000 from the admission registers of the pneumology departments of 12 hospitals in the Paris region (France). Sarcoidosis was diagnosed in 11 HIV-infected patients, of whom 8 were receiving HAART. HIV infection was diagnosed before sarcoidosis in 9 cases. At diagnosis of sarcoidosis, the mean CD4 cell count (‫ע‬SD) was cells/mm 3 , and the mean plasma virus load 390 ‫ע‬ 213 was copies/mL. Sarcoidosis occurred several months after HAART introduction, when the CD4 4002 ‫ע‬ 10,183 cell count had increased and the plasma HIV load had decreased. Clinical and radiological characteristics, laboratory values for bronchoalveolar lavage fluid samples, and outcome after a long follow-up were similar for the patients receiving HAART and for HIV-uninfected patients.
HAART reduces the incidence of opportunistic infections [1] , morbidity, and death among HIV-infected patients [2] . However, the status of various HIV-related infections can deteriorate at the outset of HAART, as recently reviewed by Shelburne et al. [3] . This paradoxical deterioration has been related to immunologic reconstitution [4] .
The onset of sarcoidosis in HIV-infected patients was documented before the HAART era [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . We recently described 2 cases of pulmonary disorders mimicking sarcoidosis in HAART-treated patients, and we found evidence of a relationship with immune reconstitution [15] . Another 9 such cases have since been reported, all of which occurred or worsened during HAART [16] [17] [18] [19] [20] [21] [22] [23] . Two other series [24, 25] reported 14 other cases of sarcoidosis diagnosed either before or after the HAART era, of which 7 occurred or worsened during receipt of HAART. The aims of this study were to identify cases of sarcoidosis in HIV-infected patients during the period 1996-2000 (the first 4 years of widespread use of HAART in France) and to describe the characteristics and long-term outcome of both HIV infection and sarcoidosis according to the treatment administered and changes in immunologic and/or virologic status.
PATIENTS AND METHODS

Study design.
Twelve pneumology departments at university hospitals in the Paris region were contacted by e-mail and asked to identify, from their admission registers, cases of sarcoidosis diagnosed in HIV-infected patients between June 1996 and December 2000. To be included in the study, patients had to have normal findings of chest radiography before the onset of sarcoidosis. Only patients who had clinical and radiological findings consistent with sarcoidosis and at least 1 biopsy specimen showing noncaseating granulomas and were followed-up for 124 months were included in the study. Infectious causes of granulomatous diseases (especially tuberculosis and mycosis) had to be excluded by microbiological analyses and by the absence of any clinical or radiological improvement in patients receiving specific treatment. The characteristics of both HIV infection and sarcoidosis were investigated according to the treatment administered (HAART and/ or steroids) and changes in plasma HIV virus load and the circulating CD4 cell count.
Published cases of sarcoidosis occurring in HIV-infected patients were identified by a Medline search of the literature published during Data collection. One physician (G.F.) used a standard form to record the characteristics of the patients from the medical files. The form gathered data on 4 groups of characteristics: (1) epidemiological characteristics (age, sex, race, and smoking history); (2) characteristics of HIV infection, including risk factor for infection, HIV disease status at hospitalization (prior diagnosis of seropositivity, according to the 1993 Centers for Disease Control and Prevention classification of HIV disease [26] ), the circulating CD4 lymphocyte count, plasma HIV virus load (limit of detection, 50 or 500 copies/mL, depending on the date and treatment center), antiretroviral treatment received (1-, 2-, 3-, or 4-drug regimens), and antimicrobial chemoprophylaxis received; (3) characteristics of sarcoidosis, including pulmonary and extrapulmonary symptoms and physical signs at the time of hospital admission, the time between onset and hospital admission, serum angiotensin-converting-enzyme levels, tuberculin skin-test results, chest radiographic aspect (stages 0-4, as recommended by DeRemee et al. [27] ), findings of whole-body 67 Ga scanning, and pulmonary function test (PFT) results, including blood gas levels while breathing room air and the diffusion capacity for carbon monoxide; and (4) outcome data for both HIV infection and sarcoidosis (physical findings, PFT results, and chest radiologic findings) and immunologic and virologic status (circulating CD4 cell count and plasma HIV virus load), as evaluated every 3-6 months from the time of diagnosis to the cut-off date for analysis (September 2002).
Particular attention was paid to the results of fiber-optic bronchoscopy and analysis of bronchoalveolar lavage (BAL) fluid specimens; that is, total and differential BAL-fluid cell counts, identification of pathogens (mycobacteria, viruses, fungi, and parasites) by appropriate staining, and culture of BAL fluid smears. CD4 and CD8 lymphocyte counts in BAL and blood specimens obtained concomitantly were also recorded. Total and differential BAL-fluid cell counts in BAL fluid from 29 control subjects were used for comparison. They were extracted from a previously published study performed by some of us [28] . Control subjects were healthy volunteers enrolled to define normal values for BAL-fluid lymphocyte subsets in our laboratory. They were 18 men and 11 women with a mean age (‫ע‬SD) of years; 9 were smokers, and 20 were 45 ‫ע‬ 12 nonsmokers. Mean age and proportion of smokers did not differ between case and control subjects.
Statistical analysis. All data are expressed as mean value (‫ע‬SD). Because of the small population size, nonparametric tests were used. Statistical comparisons were performed using the Mann-Whitney U test for unpaired data and the Wilcoxon test for paired data. P values of !.05 were considered statistically significant.
RESULTS
All 12 participating hospitals responded to our request for data, and 7 did not report any cases of sarcoidosis in HIV-infected patients. Fourteen possible cases of sarcoidosis were reported by 5 of the 12 pneumology departments. Three cases were excluded after reviewing the medical charts: in 1 case because of isolation of Mycobacterium tuberculosis from culture, in 1 case because of clinical and radiological improvement after antituberculous treatment, and in 1 case because of the absence of histological proof of sarcoid granuloma. The remaining 11 cases were included in the present study; 2 of these have been described elsewhere [15, 29] . The incidence of newly diagnosed cases of sarcoidosis in patients hospitalized in the 12 participating hospitals ranged from 30.7-125.1 cases per year during the study period, which corresponds to an incidence of HIVassociated sarcoidosis of 3.20-7.24 cases per 1000 sarcoidosispatient-years in the 5 pneumology departments in which the 11 cases were diagnosed.
Characteristics of HIV infection at the time of diagnosis of sarcoidosis. Epidemiological data and characteristics of HIV infection are summarized in table 1. HIV infection was diagnosed before sarcoidosis in 9 patients and concomitantly in 2 patients (patients 9 and 10). The interval between diagnosis of HIV infection and diagnosis of sarcoidosis was 92 ‫ע‬ 46 months.
Eight patients were receiving HAART at the time of diagnosis of sarcoidosis; the duration of HAART was months 29 ‫ע‬ 16 (range, 3-43 months). For 7 patients, HAART comprised 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 protease inhibitor; for 1 patient (patient 7), HAART comprised 2 NRTIs and 1 nonnucleoside reverse transcriptase inhibitor. The shortest interval between HAART initiation and diagnosis of sarcoidosis occurred for patient 4, who had received IL-2 immunotherapy 3 months previously. Patient 7 developed sarcoidosis 8 months after starting IFN-a therapy for chronic hepatitis C; at the time sarcoidosis was diagnosed, he had been receiving HAART for 36 months. The CD4 cell count at the (range, 10%-34%); the 22.6% ‫ע‬ 9.5% plasma HIV virus load was copies/mL (range, !50-466 ‫ע‬ 315 3500 copies/mL). All these patients had normal chest radiograph findings when HAART was started. As shown in figure  1 , CD4 cell counts increased markedly and plasma virus loads fell before the onset of sarcoidosis in patients receiving HAART.
The 3 patients (patients 8, 9, and 10) who were not receiving antiretroviral treatment at the onset of sarcoidosis had asymptomatic HIV infection. Their blood CD4 cell count at the diagnosis of sarcoidosis was cells/mm 3 (range, 168-315 ‫ע‬ 158 482 cells/mm 3 ), and their blood CD4 cell percentage was (12%-31%). The virus load was 31,000 copies/ 22% ‫ע‬ 9.5% mL in 1 patient (patient 10), not available for 1 patient (patient 9), and not determinable in 1 patient who was infected with HIV-2 (patient 8).
Characteristics of sarcoidosis. The clinical and radiological characteristics of the patients with sarcoidosis are shown in table 2. All the patients had thoracic involvement, and 8 were symptomatic. Pulmonary function tests performed for all patients showed a restrictive pattern in 3 (for patients 3, 8, and 9, the total lung capacity was !80% of the predicted value) and an obstructive pattern in 1 (for patient 4, the forced expiratory volume in 1 s was !70% of the predicted value) (data not shown). The resting partial arterial pressure of oxygen was mm Hg (range, 63-97 mm Hg), and the ratio of the 78 ‫ע‬ 10 diffusion capacity for carbon monoxide to the alveolar gas volume was (range, 32%-10%). The angiotensin-67% ‫ע‬ 23% converting-enzyme level was increased (to 11.5 times the upper limit of normal) in 5 of the 10 patients tested. Tuberculin skintest reactions were negative for all 10 patients tested.
BAL was performed for every patient (table 3) . Lymphocyte, neutrophil, and eosinophil counts in BAL fluid specimens, expressed as both the percentage of total BAL-fluid cell count and as absolute value, were significantly increased in case patients, compared with control subjects. Levels of T lymphocyte subsets were analyzed in BAL specimens from 9 patients, all but 2 of whom (patients 9 and 10) were receiving HAART at the onset of sarcoidosis. In patients receiving HAART, absolute CD4 and CD8 cell counts were both significantly higher than they were in control subjects. However, the increase in CD4 cells was greater, resulting in a significantly higher CD4:CD8 ratio in case patients than in control subjects. The CD4:CD8 cell ratio was also significantly higher in BAL fluid than in blood at the time of diagnosis of sarcoidosis (figure 2). In the 2 of the 3 patients who were not receiving HAART at the start of sarcoidosis, lymphocytic alveolitis was characterized by a predominance of CD8 cells in one patient (patient 9; CD4: CD8 ratio, 0.65) and of CD4 cells in another (patient 10; CD4: C8 ratio, 2) (data not shown); data were not available for the one other patient (patient 8).
Extrathoracic organ involvement was found, on the basis of clinical, biological, or morphological signs (including findings of 67 Ga scanning) in 6 patients (table 2), including the 3 patients who were not receiving HAART at the onset of sarcoidosis.
Treatment and outcome of HIV infection and sarcoidosis. All 11 patients were alive at the cut-off date for this analysis. HAART was never discontinued for the 8 patients who were receiving HAART at the time of diagnosis of sarcoidosis (table  2) . HAART was started for 2 of the other 3 patients (patients 9 and 10), but patient 9 subsequently stopped taking it. HAART was not prescribed to the HIV-2-seropositive patient (patient 8) (table 2) . Four patients received empirical antituberculous treatment for 2 months, and 3 did not improve (patients 2, 5, and 6). In the fourth patient (patient 9), the clinical manifestations of sarcoidosis initially improved as the immune deficiency worsened but were aggravated after initiation of HAART (and the concomitant increase in the CD4 cell count from 144 cells/mm 3 , before HAART, to 351 cells/mm 3 , 2 years later), despite renewal of antituberculous treatment.
At the cut-off date, all the patients remained asymptomatic for HIV infection, and their immunologic and virologic status had not deteriorated (figure 1). Clinical and radiological cure of sarcoidosis was noted for 3 patients, all of whom were treated with HAART. In 5 patients (1 of whom [patient 9] was not receiving HAART at the onset of sarcoidosis), sarcoidosis improved or remained stable without steroid treatment. Systemic corticosteroid therapy was given to the remaining 3 patients (patients 4, 5, and 8) for dyspnea, deterioration of PFT results, and/or progression from radiological stage 2 to stage 3. No HIV-related or steroid-related complications were observed during the treatment. In 1 patient (patient 5), sarcoidosis was cured and steroid therapy was interrupted while HAART was being administered. In the other 2 case patients, steroid therapy could not be withdrawn after 12 and 16 months of treatment, respectively. One patient was of black race (patient 8), and 1 had received IL-2 (patient 4). There was no difference in the changes in immunologic and virologic parameters between pa- tients in whom sarcoidosis was cured or improved and patients with sarcoidosis that remained stable or deteriorated.
DISCUSSION
The 11 patients described here met the usual criteria for sarcoidosis that were established for HIV-seronegative patients [30] . Their clinical histories were consistent with the diagnosis of sarcoidosis, with prominent pulmonary manifestations. The respiratory symptoms and radiological findings (mediastinal and hilar nodes and/or diffuse interstitial micronodular opacities with a predominantly perilymphatic distribution), as well as the extrathoracic involvement observed (of the salivary glands, eyes, skin, spleen, and liver) were those usually encountered in sarcoidosis. All of the patients had histological evidence of noncaseating granulomatosis disorders, as determined by intrathoracic biopsy. Other conditions usually associated with granulomatous disorders were ruled out; namely, environmental exposure, vasculitides, tumoral and infectious diseases, mycosis, and mycobacterial infection [30] . The pulmonary disorders did not improve, and sometimes worsened, in patients who received antituberculous treatment.
Our most important finding is that sarcoidosis occurred in patients receiving HAART in all but 3 cases. HIV infection is characterized by a profound alteration of the immune response components [31, 32] that are also involved in granuloma formation, namely the Th1-type CD4 cells that secrete IL-2 and INF-g [33] [34] [35] . HAART can be associated with an "immune reconstitution inflammatory syndrome" [3] . Our findings suggest that sarcoidosis may be related to recovery of late memory and/or naive CD4 lymphocytes during HAART. Sarcoidosis generally occurred after marked increases in the CD4 cell count and a marked decreases in HIV load (figure 1). Granuloma formation was found in the lungs of all the patients. It was associated with CD4 cell recruitment from blood (figure 2) and mainly consisted of CD4 cells [15] . Recovery of Th1-type (memory) CD4 cell functions has been implicated in paradoxical aggravation of infectious granulomatous disorders (i.e., tuberculosis and other mycobacterial infections) [3, 36, 37] . However, the mean interval between HAART introduction and pulmonary onset in our patients with sarcoidosis was much longer (several months) than that reported for granulomatous disorders of infectious origin (a few weeks) [36, 37] . This suggests the involvement of the naive CD4 cell pool, which has been shown to expand later than the memory cell pool in HIVinfected patients receiving HAART [4] . It is interesting to note that sarcoidosis developed more rapidly in the 2 patients also receiving Th1 cytokines (IL-2 and IFN), which are known to play a pivotal role in granuloma formation [33, 35] .
In 3 patients, sarcoidosis occurred in the absence of HAART and was diagnosed at the same time as HIV infection. All 3 patients were of black race, which is a known risk factor for sarcoidosis [38] , as is extrathoracic involvement [39] , which was also observed in these patients. Findings for these patients were similar to those for cases that occurred before the HAART era [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , especially regarding the predominantly CD8-lymphocytic alveolitis in 1 case patient (patient 9) [6, 8, 9, 12] , which has been related to HIV infection itself [40] . In this latter patient, the sarcoidosis first improved radiologically as the CD4 cell count fell, then worsened 2 years after initiation of HAART, as recently reported [17, 22] .
The course of sarcoidosis in our patients was similar to that observed in HIV-seronegative patients [30] . Most recovered or improved spontaneously, or remained stable, after lengthy follow-up, as did almost all those with a stage 1 or 2 radiological pattern [41] . In these patients, HAART was never withdrawn and immunologic parameters did not deteriorate (figure 1). Steroid treatment was needed in some patients and could not be interrupted for those with particular risk factors, namely a patient of black race with pulmonary and extrapulmonary sar-coidosis [30] and a patient receiving IL-2 who developed an obstructive ventilatory disorder [41] .
In conclusion, sarcoidosis can occur in HIV-infected patients with long-term immunologic reconstitution during HAART. Treatment with IL-2 or IFN-a 2a may be a risk factor for sarcoidosis. Clinical and radiological findings, BAL-fluid analysis findings, and outcome are similar to those observed for HIV-uninfected patients.
